Navigation Links
Cholesterol Drug Controversy Continues
Date:3/30/2008

Doctors debate worth of lipid-lowering agent that combines 2 medications

SUNDAY, March 30 (HealthDay News) -- A divided cardiology community is trying once again to make sense of a trial showing that a drug can lower levels of "bad" LDL cholesterol and yet give no apparent benefit to people at high risk of heart attack and other cardiovascular problems.

The drug, Vytorin, combines a well-known statin -- simvastatin -- with ezetimibe, which also lowers LDL cholesterol, but in a different way. A controversy erupted earlier this year when Merck/Schering-Plough, which markets the drug in the United States, released results of a European trial that showed the combined medication did not reduce buildup of potentially artery-blocking plaque deposits any more than simvastatin alone.

Those results and their implications are being discussed this weekend at the American College of Cardiology annual meeting, in Chicago. The New England Journal of Medicine, which will publish two papers and two editorials on the drug in its April 3 issue, is releasing the papers early to coincide with the meeting.

One paper by European researchers goes over the trial results again and comes to the same conclusion: Vytorin did not reduce plaque buildup any more than statin treatment alone in the study group -- people with an inherited condition that causes them to have an unusually high level of blood cholesterol and a resulting higher risk of cardiovascular problems early in life.

Then the interpretation of those results begins.

Dr. B. Greg Brown, a professor of medicine at the University of Washington School of Medicine in Seattle, who co-authored one of the editorials, said the results might not apply to the general population because "this population [in the study] had been treated for many years because they had a very high cholesterol level. That might affect their response to the new treatment."

The basic question remains unanswered, Brown said. "The drug [Vytorin] does lower LDL cholesterol very effectively. The question is, does it help reduce the risk of heart attack or stroke or things like them? Is it cosmetic or is there a risk reduction as well?"

Those questions have yet to be answered, Brown said. But, he added, "my sense is that this was the wrong population to study." Other studies now under way might provide an answer, but not until 2011 or 2012, he said.

Meanwhile, Brown said, "I agree with the statements made by the American Heart Association and the American College of Cardiology, to use ezetimibe if it is needed to get people down to a target level of LDL cholesterol."

Dr. Harlan M. Krumholz, a professor of medicine at Yale University School of Medicine and co-author of another of the journal papers, disagreed with Brown's view.

"For myself, I would not take the medication, and if I recommended it to anyone, it would be for the highest-risk patient who couldn't tolerate statins," Krumholz said.

The paper he co-authored compared use of Vytorin in the United States and Canada. The proportion of cholesterol-lowering drug prescriptions represented by Vytorin rose from 0.2 percent to 3.4 percent in Canada from 2002 to 2006. In the United States, the increase was from 0.1 percent to 15.2 percent of all such prescriptions.

"That is a pretty remarkable difference," Krumholz said. "If we had adopted the drug at the same speed as in Canada, we would have saved $1.5 to $2 billion in health-care costs. What did we get for that? Did it produce benefits for patients? We can't say we're sure of that."

It's also possible that the new cholesterol-lowering agent might turn out to be harmful, Krumholz said. He recalled the history of torcetrapib, a drug developed by Pfizer that increased blood levels of HDL cholesterol, the "good" kind that prevents plaque formation. Pfizer stopped tests of the drug in 2006 because of a trial showing higher mortality among those taking it.

"It was a new drug, the first in its class," Krumholz said. "The laboratory results looked great, and it ended up hurting people."

It's not clear whether the same will be true of Vytorin, he said. "The evidence we have on hand makes a benefit less likely," Krumholz said. "We have a $5-billion-a-year market without outcomes data."

His journal paper noted that use of statins remained constant in Canada but has declined in the United States as use of Vytorin rose.

"We did not push statins to the maximum," Krumholz said. "That is definitely the wrong thing to do."

More information

The various kinds of cholesterol and what can be done about them are described by the American Heart Association.



SOURCES: B. Greg Brown, M.D., professor, medicine, University of Washington School of Medicine, Seattle; Harlan Krumholz, M.D., professor, medicine, Yale University School of Medicine; March 30, 2008, presentation, American College of Cardiology annual meeting, Chicago; April 3, 2008, New England Journal of Medicine


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Premature Delivery Linked to High Cholesterol in Moms Later
2. One-Third of U.S. Primary Care Physicians and Cardiologists Do Not Currently Prescribe Treatment to Meet HDL Cholesterol Targets as Recommended By National Guidelines
3. Study shows cholesterol-lowering power of dietitian visits
4. Cholesterol-Lowering Statins Tied to Tendon Woes
5. Cholesterol-Lowering Drugs May Ease Irregular Heartbeat
6. Children May Have Cholesterol Problems, Too
7. PreMD Announces FDA Decision on POC Skin Cholesterol Test
8. Cholesterol Drug Zetia Doesnt Cut Heart Attack Risk: Study
9. Seven New Cholesterol Genes Discovered
10. Corazonas Launches First and Only Cholesterol-Reducing Potato Chips
11. High triglycerides, other cholesterol raise risk of stroke
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cholesterol Drug Controversy Continues
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... medical dynamometers and ergoFET force gauges used in physical therapy, occupational therapy and ... Indicator sensor for resistance cord exercise and therapy, introduces its new microFET Digital ...
(Date:2/11/2016)... , ... February 11, 2016 , ... As part of ... of the Million Dollar Round Table Foundation (MDRTF), has gifted $10,000 to University of ... Colleen’s Dream Foundation President Billy Cundiff. , “We are honored to support a promising ...
(Date:2/10/2016)... ... ... LaserShip, a regional parcel carrier that services the eastern U.S., donated and ... in order to aid in the Flint water crisis. In 2014, LaserShip acquired Prestige ... Clio, only 15 miles away from Flint. , “We have deep roots in the ...
(Date:2/10/2016)... ... February 10, 2016 , ... InDemand Interpreting ... Healthcare, recently partnered with Heart City Health Center to improve access ... years, Heart City Health Center has provided the Elkhart community with access to ...
(Date:2/10/2016)... ... February 10, 2016 , ... 10 Best Water is ... leading bottled water brand owners that topped the list as a result of their ... conversion. The premier brand was Tibet 5100, a top notch water company that specializes ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , February 10, 2016 A ... which will be held at Victoria Park Plaza in ... an informative seminar on technology and future advances for late ... led by Lorna Graham , associate director of project ... to keep up with new regulations and standards in late ...
(Date:2/10/2016)... Puerto Rico Healthcare and Life Sciences Report 2016 ... Report 2016 . --> Focus Reports releases ... Sciences Report 2016 . pharmaceuticals , or ... world for pharma manufacturing, a territory with significantly improved capabilities ... per square mile than anywhere else on the planet. ...
(Date:2/10/2016)... , Feb. 10, 2016 Convergence ... confluence of various technologies that results in ... unavailable. These opportunities create a cyclical system ... turn, drives the development of new technologies. ... characterized by technology convergences, which are constantly ...
Breaking Medicine Technology: